Rett Syndrome Pipeline Assessment, 2024 Updates | Clinical Trials, Drugs, Latest FDA Approvals, Companies | Neuren Pharmaceuticals, Novartis, Neurolixis, Vyant Bio, AMO Pharma, Prilenia Therapeutics

Rett Syndrome Pipeline Assessment, 2024 Updates | Clinical Trials, Drugs, Latest FDA Approvals, Companies | Neuren Pharmaceuticals, Novartis, Neurolixis, Vyant Bio, AMO Pharma, Prilenia Therapeutics
Rett Syndrome Pipeline Insights
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Rett Syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Rett Syndrome Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Rett Syndrome Market. 

The Rett Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Rett Syndrome Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Rett Syndrome and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Rett Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Route of Administration

Rett Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical


Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides 

  • Polymer 

  • Small molecule

  • Gene therapy


Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Learn How the Ongoing Clinical & Commercial Activities will Affect the Rett Syndrome Therapeutic Segment @

Rett Syndrome Therapeutics Landscape

There are approx. 20+ key companies developing therapies for Rett Syndrome. Currently, Neuren Pharmaceuticals has its Rett Syndrome drug candidates in the most advanced stage of clinical development among all the key players. 

The Leading Companies in the Rett Syndrome Market Include:

  • Neuren Pharmaceuticals

  • Anavex Life Sciences

  • Edison Pharmaceuticals

  • Novartis

  • Ultragenyx Pharmaceutical

  • GW Pharmaceuticals

  • Q-State Biosciences

  • AveXis

  • AMO Pharma

  • Neurolixis

  • Biohaven Pharmaceuticals

  • Echo Pharmaceuticals

  •  Vyant Bio

  • Prilenia Therapeutics

  • StrideBio

  • Relmada Therapeutics

  • VICO Therapeutics

  • Taysha Gene Therapies

  • Sarepta therapeutics

And Many Others

Rett Syndrome Drugs Covered in the Report Include:

  • Trofinetide: Neuren Pharmaceuticals

  • ANAVEX2-73 (blarcamesine): Anavex Life Sciences

  • VYNT-0126: Vyant Bio, Inc.

  • ORAI-xxxx: Vyant Bio, Inc.

  • GWP42003-P: GW Research Ltd 

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Contents

1. Report Introduction

2. Executive Summary

3. Rett Syndrome Current Treatment Patterns

4. Rett Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Rett Syndrome Late Stage Products (Phase-III)

7. Rett Syndrome Mid-Stage Products (Phase-II)

8. Rett Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Rett Syndrome Discontinued Products

13. Rett Syndrome Product Profiles

14. Key Companies in the Rett Syndrome Market

15. Key Products in the Rett Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Rett Syndrome Unmet Needs

18. Rett Syndrome Future Perspectives

19. Rett Syndrome Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States